Anticancer siRNAs Delivered to Cells Using MOF Nanoparticles

Scientists from the University of Cambridge have developed a highly porous type of nanoparticle known as a metal-organic framework (MOF) that can deliver disease gene targeting small interfering RNAs (siRNAs) directly to cells. There...

Study shows invasive blue catfish can tolerate high salinities

Indicates potential for further expansion in Chesapeake and into Delaware Bay Credit: © VIMS Trawl Survey. A new study by researchers at the Virginia Institute of Marine Science...

NIH grants 4D Nucleome award to support research by Gladstone scientists

Reviewed by Emily Henderson, B.Sc.Oct 15 2020 The National Institutes of Health (NIH) has granted a 4D Nucleome award to support research by a group of scientists at Gladstone Institutes led by Benoit Bruneau, PhD,...

Background Press Call on President Biden’s Executive Order to Launch a National Biotechnology and...

Via Teleconference (September 11, 2022) 4:01 P.M. EDT MODERATOR:  Hi, everyone.  And thanks for joining us on a Sunday.  The purpose of today’s call will be to preview the President’s executive order, which he’ll sign tomorrow,...

Heavyweight Division: Arvinas Paves the Way for Therapeutics That Degrade Disease-Related Proteins

Arvinas is a clinical-stage biotechnology company that has developed an induced protein degradation strategy to recruit targeted proteins for ubiquitination and subsequent proteasome-mediated degradation. The technology, called Proteolysis Targeting Chimeras (PROTACs), shows great potential...

Phlow

Candidates: Various generic therapeutics against COVID-19 Types: Not specified Status: Phlow, a public benefit drug manufacturing corporation, announced May 19 that it received a commitment of up to $812 million over 10 years from the Biomedical...

Synbal and La Jolla Institute for Immunology collaborate to develop better COVID-19 models

The La Jolla Institute for Immunology (LJI) is partnering with Synbal, Inc., a preclinical biotechnology company based in San Diego, CA, to develop multi-gene, humanized mouse models for COVID-19 research. The research at LJI...

Dicerna, Novo Nordisk Eye 30+ Liver Targets in Up-to-$3.8B RNAi Partnership

Novo Nordisk will apply Dicerna Pharmaceuticals’ GalXC platform to discover and develop RNA interference (RNAi) therapies for liver-related cardio-metabolic diseases, the companies said this week, through a collaboration that could generate more than $3.8...

Hepatitis B Virus Uses Host’s DNA Repair Proteins to Close Circle of Infection

To establish chronic disease, the hepatitis B virus (HBV) must have its genome of relaxed circular DNA (rcDNA) turned into covalently closed circular DNA (cccDNA). Exactly how rcDNA becomes cccDNA has been unclear, but...

Quantum copycat: Researchers find a new way in which bosons behave like fermions

Credit: Nate Follmer, Penn State Bosons and fermions, the two classes into which all particles–from the sub-atomic to atoms themselves–can be sorted, behave very differently under most...